Streetbeat News

Analyst Ratings

MRNS

RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Marinus Pharma (NASDAQ:MRNS), maintaining a $24 price target.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 3:13 pm

FNV

BMO Capital analyst Jackie Przybylowski maintains an Outperform rating on Franco-Nevada, but lowers the price target from C$200 to C$195.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 3:13 pm

MA

Wells Fargo analyst Donald Fandetti maintains an Overweight rating on Mastercard (NYSE:MA) and raises the price target from $490 to $530.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 3:13 pm

V

Wells Fargo analyst Donald Fandetti has maintained an Overweight rating on Visa (NYSE:V) and increased the price target from $300 to $325.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 3:11 pm

TGT

BMO Capital analyst Kelly Bania maintains a Market Perform rating on Target Corporation (NYSE:TGT) and raises the price target from $145 to $170.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 3:06 pm

ROST

BMO Capital analyst Simeon Siegel maintains an Outperform rating on Ross Stores (NASDAQ:ROST) and raises the price target from $138 to $165.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 3:04 pm

FERG

RBC Capital analyst Mike Dahl has maintained an Outperform rating on Ferguson (NYSE:FERG) and increased the price target from $202 to $217.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 3:04 pm